8-K: Passage Bio Receives Positive FDA Feedback to Expand FTD Trial to Include C9orf72 Patients

Passage Bio announced positive feedback from the FDA regarding their proposal to expand the upliFT-D trial of PBFT02 to include frontotemporal dementia patients with C9orf72 gene mutations.

Summary

• Passage Bio received positive feedback from the FDA on their proposal to expand the upliFT-D trial for PBFT02 to include patients with frontotemporal dementia (FTD) who have mutations in the C9orf72 gene.
• The company plans to amend the ongoing upliFT-D Phase 1/2 global study to include this new patient population.
• Dosing of FTD-C9orf72 patients is expected to begin in the first half of 2025.
• This expansion is supported by preclinical evidence and safety data from the first cohort of FTD-GRN patients treated with PBFT02.
• FTD-C9orf72 affects an estimated 21,000 individuals in the United States and Europe.
• PBFT02 has received Fast Track and Orphan Drug designations from the FDA, and an Orphan designation from the European Commission.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the favorable FDA feedback and the planned expansion of the clinical trial. The company is making progress in a critical area of unmet need.

Positives

• The FDA's positive feedback supports the expansion of the PBFT02 trial to a new patient population.
• The company has a clear timeline for initiating dosing of FTD-C9orf72 patients in the first half of 2025.
• PBFT02 has received key regulatory designations, including Fast Track and Orphan Drug status, which can expedite development and approval.
• Preclinical data and early clinical data from FTD-GRN patients support the expansion of the trial.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the ability to obtain regulatory approval, the timing and results of clinical trials, and the occurrence of adverse safety events.
• There are risks associated with the company's dependence on collaborators and third parties.
• The company faces risks associated with current and potential delays, work stoppages, or supply chain disruptions.

Future Outlook

Passage Bio plans to submit the revised trial protocol to health authorities and ethics committees promptly and expects to initiate dosing of FTD-C9orf72 patients in the first half of 2025. The company will continue to advance the clinical development of PBFT02.

Management Comments

• Securing FDA alignment on amending our upliFT-D protocol to include FTD-C9orf72 patients is a critical milestone in expanding access to those who could benefit from PBFT02, said Will Chou, M.D., president and chief executive officer of Passage Bio.
• Given the limited clinical trials for FTD-C9orf72 patients, we believe PBFT02 could fill a significant unmet need and bring new hope to this underserved patient community.

Industry Context

This announcement is significant as it addresses a critical unmet need in the treatment of FTD-C9orf72, a neurodegenerative disease with limited clinical trial options. The expansion of the trial reflects a broader trend in the industry towards developing targeted therapies for genetic forms of neurodegenerative diseases.

Comparison to Industry Standards

• The expansion of the upliFT-D trial to include FTD-C9orf72 patients is a positive step, as many companies are focusing on specific genetic mutations in neurodegenerative diseases.
• Other companies like Denali Therapeutics and Biogen are also developing therapies for neurodegenerative diseases, but Passage Bio's focus on gene therapy and specific mutations like C9orf72 sets them apart.
• The Fast Track and Orphan Drug designations for PBFT02 are consistent with industry trends where regulatory agencies are prioritizing therapies for rare and serious diseases.

Stakeholder Impact

• Shareholders will likely view the positive FDA feedback and trial expansion as a positive development.
• Patients with FTD-C9orf72 and their families may have increased hope for a potential treatment option.
• Employees of Passage Bio may be motivated by the progress of the clinical trial.
• The company's collaborators and partners will be involved in the execution of the trial expansion.

Next Steps

• Passage Bio will submit the revised trial protocol to health authorities and ethics committees.
• The company plans to initiate dosing of FTD-C9orf72 patients in the first half of 2025.

Key Dates

Keywords

PBFT02, Frontotemporal Dementia, FTD, C9orf72, FDA, Clinical Trial, Neurodegenerative Diseases, Progranulin, PGRN, Genetic Medicines